Researchers have discovered genetic variations that may predict risk of death and help direct treatment for lung cancer patients. The researchers analyzed the DNA of patients with non-small cell lung cancer (NSCLC), looking for variations associated with survival. Four of the variants they identified were located on the same gene, called TNFRSF10B. Patients with these genetic variants had up to a 41% higher chance of death, especially if they were treated with surgery only. In contrast, if these patients received chemotherapy after surgery, their risk of death was not increased. The genetic variants may therefore be useful biomarkers for guiding treatment decisions.